首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 199 毫秒
1.
目的探讨金雀异黄素对5/6肾切除大鼠的。肾脏保护作用。方法将5/6肾切除大鼠分为金雀异黄素组(Gen)和模型对照组(Con),同时设假手术组(So)为正常对照组。检测各组术后第4、8周尿蛋白、血肌酐、尿素氮、血白蛋白、总蛋白等水平,观察第8周肾组织的病理改变情况。应用免疫组化方法检测肾组织中纤维连接蛋白(FN)和Ⅳ型胶原(ColⅣ)沉积的情况。采用Western Blot法检测肾组织中TGF-β,蛋白质表达的情况。结果与模型对照组相比,金雀异黄素组尿蛋白排泄量明显减少,血肌酐、尿素氮水平明显下降,肾小球硬化程度明显减轻,肾小球内FN和COlⅣ沉积显著减少,TGF-β1,蛋白质表达明显减弱。结论金雀异黄素对5/6肾切除大鼠肾脏病变有部分保护作用。  相似文献   

2.
目的 探讨大豆黄素对5/6肾切除大鼠肾脏的保护作用及其机制。方法将26只雌性SD大鼠分为3组:假手术组(S组)8只,5/6肾切除模型组(M组)8只,大豆黄素治疗组(D组)10只。对M组和D组大鼠建立5/6肾切除模型,D组给予大豆黄素15mg·kg^-1·d^-1灌胃,M组给予等量生理盐水灌胃,共8周。检测各组大鼠治疗前、后24h尿蛋白定量、血肌酐(SCr)、尿素氮(BUN)、血清总蛋白(TP)和清蛋白(Alb),观察肾组织病理学表现,检测肾组织纤维连接蛋白(FN)、Ⅳ型胶原和转化生长因子β1(TGFβ1)表达。结果与M组相比,D组24h尿蛋白量、SCr、BUN降低(P〈0.05);肾小球硬化指数降低(P〈0.05);肾组织FN和Ⅳ型胶原蛋白表达降低(P〈0.01);TGF-β1mRNA及其蛋白表达降低(P〈0.05)。结论大豆黄素对5/6肾切除大鼠肾脏有保护作用,可能与其抑制肾组织TGF-β1的表达有关。  相似文献   

3.
褐藻多糖硫酸酯对阿霉素肾病肾硬化大鼠肾脏的保护作用   总被引:1,自引:1,他引:0  
目的:观察褐藻多糖硫酸酯(FPS)对阿霉素肾病肾硬化大鼠肾脏的保护作用并探讨其可能的机制.方法:将SD大鼠随机分成4组:假手术组(SHAM组)、阿霉素肾病肾硬化模型组(M组)、褐藻多糖硫酸酯治疗组(FPS组)、贝那普利对照组(B组).8周后观察大鼠24 h尿蛋白定量、血尿素氮(BUN)、肌酐(Scr);以及肾脏病理改变;并用免疫组化观察肾脏组织纤连蛋白(FN)、Ⅳ型胶原(Col-Ⅳ)、转化生长因子β1(TGF-β1)的表达;用RT-PCR的方法测定肾实质TGF-β1和纤溶酶原激活物抑制物(PAI-1)mRNA的表达.结果:FPS能减少尿蛋白、降低 BUN和Scr.减轻基质增生和肾小球硬化.减少TGF-β1、FN、Col-Ⅳ的表达,下调肾皮质中TGF-β1、PAI-1 mRNA的表达.结论:FPS能减轻阿霉素肾病肾硬化大鼠的肾脏损害,对肾脏具有保护作用.  相似文献   

4.
血管紧张素II受体拮抗剂对5/6肾切除鼠的肾脏保护作用   总被引:3,自引:0,他引:3  
目的:探讨血管紧张素II受体拮抗剂氯沙坦对5/6肾切除大鼠肾脏病变的保护作用。方法:将5/6肾切除鼠分为氯沙坦治疗组和对照组,设假手术组为正常对照,检测各组术后第2,4,6周的尿蛋白及第6周的血清尿素氮,肌酐,总蛋白,白蛋白,观察第6周肾组织的病理改变,并应用免疫组织化学方法检测肾组织内纤维连接蛋白(FN)和IV型胶原在肾小球的沉积,结果:氯沙坦治疗组比对照组尿蛋白排泄量明显减少(P<0.01),血肌酐,尿素氮水平下降(P<0.01),肾小球增生,硬化程度明显减轻;免疫组织化学显示,对照组 小球内FN和IV型胶原沉积增多,治疗组FN和IV型胶原沉积比对照组减少(P<0.01),结论:氯沙坦对5/6肾切除鼠肾脏闰变有部分保护作用。  相似文献   

5.
血管紧张素Ⅱ受体拮抗剂对5/6肾切除鼠的肾脏保护作用   总被引:8,自引:1,他引:7  
目的探讨血管紧张素Ⅱ受体拮抗剂氯沙坦对5/6肾切除大鼠肾脏病变的保护作用。方法将5/6肾切除鼠分为氯沙坦治疗组和对照组,设假手术组为正常对照。检测各组术后第2、4、6周的尿蛋白及第6周的血清尿素氮、肌酐、总蛋白、白蛋白,观察第6周肾组织病理改变,并应用免疫组织化学方法检测肾组织内纤维连接蛋白(FN)和Ⅳ型胶原在肾小球的沉积。结果氯沙坦治疗组比对照组尿蛋白排泄量明显减少(P<0.01),血肌酐、尿素氮水平下降(P<0.01),肾小球增生、硬化程度明显减轻;免疫组织化学显示,对照组肾小球内FN和Ⅳ型胶原沉积增多,治疗组FN和IV型胶原沉积比对照组减少(P<0.01)。结论氯沙坦对5/6肾切除鼠肾脏病变有部分保护作用。  相似文献   

6.
目的:探讨来氟米特对5/6肾切除大鼠转化生长因子-β1(TGF-β1)表达的影响。方法:将36只SD大鼠随机分为假手术组(A组)12只和手术组24只,术后3d再将手术组大鼠随机分为模型组(B组)12只和来氟米特组(C组)12只。第4,9周末各组随机选取6只大鼠处死并收集标本,记录血肌酐、尿素氮、胆固醇、三酰甘油、白蛋白及24h尿蛋白排泄量;取肾组织做病理检查,用RT-PCR方法测定肾皮质TGF-β1 mRNA的表达,免疫组化(SP法)检测TGF-β1在肾脏的表达。结果:(1)与A组相比,B组和C组大鼠造模成功后4周末尿素氮、肌酐、血脂等无明显变化(P〉0.05);B组24h尿蛋白排泄量明显增加(P〈0.01),血白蛋白下降(P〈0.01),肾皮质TGF-β1 mRNA表达明显增加(P均〈0.05)。9周末B组肾皮质TGF-β1 mRNA表达量、尿素氮、肌酐、胆固醇明显增加(P〈0.05),24h尿蛋白排泄量增加更为明显(P〈0.05)。(2)与B组相比,C组24h尿蛋白排泄量明显下降(P均〈0.01);于9周末尿素氮、肌酐、胆固醇明显降低(P〈0.05);血白蛋白升高(P〈0.05),肾小球硬化指数下降(P〈0.01),肾皮质TGF-β1 mRNA表达量明显下降(P〈0.01)。免疫组织化学染色:B组可见系膜区TGF-β1大量沉积,C组也可见TGF-β1沉积,但较B组明显减轻。结论:来氟米特能减少5/6肾切除大鼠尿蛋白排泄量,纠正其脂代谢紊乱,减轻肾脏的硬化程度,其机制可能与下调系膜细胞上TGF-β1 mRNA的表达量及功能活性有关,最终延缓慢性肾脏病的进展。  相似文献   

7.
目的:研究TGF-β1及FN在狼疮样小鼠肾组织中的表达及霉酚酸酯(MMF)的干预作用。方法:建立cGVHD狼疮样小鼠模型。按随机设计原则将模型动物分两组即模型组和MMF治疗组,另设正常对照组。检测各组小鼠血肌酐、尿素氮及尿蛋白的变化,用HE染色观察肾组织纤维化程度,以Real-time PCR检测各组小鼠肾组织中TGF-β1及FN的mRNA丰度,并用Western blotting方法检测各组小鼠肾组织中TGF-β1及FN的蛋白表达情况。结果:12周模型组的小鼠肾小球系膜节段、弥漫性增生,且血肌酐、尿素氮及尿蛋白较正常对照组均明显增加,Real-timePCR及Western blotting结果证实模型组小鼠的肾组织中TGF-β1及FN的mRNA和蛋白表达水平与正常组相比水平均明显增加,而MMF治疗组与模型组相比其TGF-β1及FN的mRNA和蛋白表达均降低,且血肌酐、尿素氮及尿蛋白水平也有所降低。结论:TGF-β1可能参与了狼疮肾炎的发病,MMF可能通过抑制肾组织TGF-β1的表达来改善狼疮肾炎的增生病变。  相似文献   

8.
目的 观察肾素抑制剂阿利吉仑对2型糖尿病db/db小鼠肾脏损伤的保护作用。 方法 8周龄db/db和db/m小鼠行单侧肾切除,16周进入实验,分为4组:db/m小鼠对照组(db/m组)、db/db糖尿病小鼠对照组(db/db组)、db/db糖尿病小鼠阿利吉仑3 mg&#8226;kg-1&#8226;d-1治疗组(db/db+A3组)和db/db糖尿病小鼠阿利吉仑25 mg&#8226;kg-1&#8226;d-1治疗组(db/db+A25组)。阿利吉仑溶于磷酸盐缓冲液(PBS,350 mg/L)皮下泵入(0.25 μl/h)给药,疗程4周。治疗前后检测体质量、血糖、糖化血红蛋白、尿蛋白量、血压水平;PAS染色观察肾脏组织学变化;ELISA法检测肾皮质转化生长因子β1(TGF-β1)和纤溶酶原激活抑制因子1(PAI-1)含量;间接免疫荧光检测肾小球Ⅳ型胶原(ColⅣ)和纤连蛋白(FN)表达;实时定量PCR检测TGF-β1、PAI-1、ColⅣ、FN和肾素mRNA表达;放射免疫法检测肾皮质肾素活性和血管紧张素Ⅱ(AngⅡ)水平。 结果 与db/m组小鼠比较,db/db组小鼠有大量蛋白尿,肾小球细胞外基质沉积增加,TGF-β1、PAI-1、ColⅣ和FN蛋白及mRNA表达增加,同时肾皮质肾素mRNA、肾素活性和AngⅡ水平增高(均P < 0.05)。阿利吉仑25 mg&#8226;kg-1&#8226;d-1治疗在没有影响血压情况下,显著减少db/db小鼠24 h尿蛋白量,减少肾小球细胞外基质沉积,减少TGF-β1、PAI-1、ColⅣ、FN蛋白和mRNA表达,同时降低肾皮质肾素活性和AngⅡ水平(均P < 0.05)。 结论 阿利吉仑对2型糖尿病db/db小鼠肾脏损伤有保护作用。  相似文献   

9.
糖肾方对糖尿病肾病大鼠肾组织TGF-β1及MMP-9表达的影响   总被引:1,自引:0,他引:1  
目的:研究糖肾方对糖尿病肾病大鼠肾组织TGF-β1、MMP-2、MMP-9及Ⅳ型胶原表达的影响,探讨糖肾方对糖尿病肾病大鼠肾脏的保护机制。方法:50只Wistar大鼠随机分为空白组、模型组、蒙诺组(0.833mg/kg)、糖肾方大剂量组(2.67g/kg)、糖肾方小剂量组(1.33g/kg),每组10只,利用单侧肾切除加腹腔注射链脲佐菌素造成糖尿病肾病大鼠模型,连续给药20周。动态检测血糖和尿蛋白/肌酐水平;取肾组织进行病理组织学观察并对肾小球硬化和肾小管间质纤维化程度进行评分;RT-PCR方法检测TGF-β1、MMP-2及MMP-9 mRNA表达,免疫组化方法检测肾组织TGF-β1及Ⅳ型胶原表达。结果:大剂量糖肾方能显著降低糖尿病肾病大鼠尿蛋白/肌酐(P〈0.05),降低肾小球硬化指数(P〈0.01)和肾小管间质纤维化指数(P〈0.01),减少TGF-β1mRNA与蛋白表达(P〈0.05),增加MMP-9mRNA表达(P〈0.05),减少Ⅳ型胶原蛋白表达(P〈0.05)。结论:糖肾方可减轻实验大鼠肾小球硬化和肾小管间质纤维化,其作用机制可能与抑制TGF-β1表达和提高MMP-9mRNA水平有关。  相似文献   

10.
全反式维甲酸对大鼠肾小球硬化模型肾脏的保护作用   总被引:2,自引:0,他引:2  
目的:探讨全反式维甲酸对大鼠肾小球硬化模型肾脏的保护作用.方法:用单侧肾切除加1周后静脉注射阿霉素(5 mg/kg)的方法建立大鼠肾小球硬化模型,分模型对照组、全反式维甲酸治疗组和苯那普利治疗组,设假手术组为正常对照组.检测各组术后第2、4、6周的尿蛋白及第6周的血清尿素氮、肌酐、总蛋白、白蛋白及肾组织病理改变,并应用免疫组化方法检测肾组织内纤连蛋白(FN)、层黏蛋白(LN)在肾小球的沉积和转化生长因子-β1(TGF-β1)蛋白质的表达.结果:全反式维甲酸和苯那普利治疗组比模型对照组尿蛋白排泄量明显减少,血肌酐和尿素氮水平下降,肾小球增生、硬化程度明显减轻(P<0.05) ;免疫组化显示,模型对照组肾小球内FN和LN沉积增多,肾小管上皮细胞TGF-β1蛋白表达增高,全反式维甲酸和苯那普利治疗组则较模型对照组减少(P<0.05), 但二者间无明显差别(P>0.05).结论:同苯那普利一样,全反式维甲酸对大鼠肾小球硬化模型肾脏病变有部分保护作用.  相似文献   

11.
目的观察大豆蛋白饮食对5/6肾切除大鼠血管早期病变的影响并探讨其可能的机制。方法把40只大鼠随机分为手术组和假手术组,手术组大鼠行5/6肾切除术后又随机分为对照组(20%酪蛋白),低蛋白组(6%酪蛋白),大豆蛋白组(6%大豆蛋白)。假手术组予以普通酪蛋白饲料饮食。于术前、术后4周、8周及12周观察大鼠的营养状况,并检测其血清尿素氮(BUN)、肌酐(Scr)、胆固醇(TC)、三酰甘油(TG)、白蛋白(Alb)以及尿蛋白量(24h)等指标。12周后处死所有大鼠,并留取其主动脉弓组织,行HE染色观察主动脉弓病理变化,并行免疫组化染色检测其单核细胞趋化蛋白(MCP)1和植物血凝素样氧化低密度脂蛋白受体(LOX)1的表达水平。结果5/6肾切除大鼠各组BUN、Scr从第4周起均开始升高,但低蛋白组及大豆蛋白组BUN、Scr上升的程度较对照组缓慢,且以大豆蛋白组最为显著[12周Scr,(111.44±5.50)比(172.00±9.54)μmol/L,P〈0.01]。与假手术组相比,5/6肾切除大鼠各组血白蛋白水平均显著降低(P〈0.01),但各手术组间差异无统计学意义。5/6肾切除大鼠各组尿蛋白量(24h)随时间的延长持续增加,但低蛋白组、大豆蛋白组的增加幅度较小(P〈0.01)。各组大鼠主动脉弓组织未见明显病理改变。免疫组化检查发现,大豆蛋白组大鼠主动脉弓内膜MCP-1(155.68±4.84比132.80±5.67)和LOX-1(195.48±4.95比167.46±7.62)染色灰度值明显高于对照组(P〈0.01)。结论大豆蛋白饮食能有效抑制5/6肾切除大鼠的大动脉内膜的MCP-1和LOX-1的表达,提示大豆蛋白饮食有助于减轻慢性肾衰大鼠的早期血管病变。  相似文献   

12.
13.
目的观察低蛋白加α酮酸饮食对5/6肾切除大鼠模型的残余肾功能保护作用及对肾组织炎症反应的影响,并探讨其可能的作用机制。方法30只SD雄性大鼠随机分为3组后行5/6肾切除,术后给予不同的饮食:低蛋白加酮酸组(4%酪蛋白+2%α酮酸)、低蛋白组(6%酪蛋白)和高蛋白组(20%酪蛋白),同时设10只SD雄性大鼠为假手术对照组(20%酪蛋白)。检测术前及术后第4、8、12周各组尿蛋白、血白蛋白、Ser、BUN等指标。12周后处死大鼠,观察肾组织病理改变;免疫组化方法检测肾组织单核巨噬细胞抗原(ED-1)、单核细胞化学吸引蛋白质1(MCP-1)及RANTES的表达情况。结果(1)术后4周起,3个切除组Scr、BUN及尿蛋白均持续升高,其中以高蛋白组最显著(P<0.01),而低蛋白加酮酸组升高最为缓慢;第12周时,低蛋白加酮酸组显著低于其余2组[Scr为(125.44±5.50)比(172.00±9.54)、(135.22±5.78)μmol/L;尿蛋白量(24h)为(28.36±3.69)比(92.32±34.06)、(46.62±6.19)mg,P<0.01。(2)与高蛋白组和低蛋白组相比,低蛋白加酮酸组肾组织损害明显减轻,肾小球病理积分为0.38±0.13比0.84±0.28、0.49±0.11,P<0.01。(3)低蛋白加酮酸组肾小管间质内MCP-1、RANTES的表达比高蛋白组及低蛋白组显著减少,同时ED-1的阳性细胞数也明显减少[肾小管间质ED-1阳性细胞为(3.59±0.78)个比(13.33±1.20)、(6.50±0.99)个,P<0.05。结论低蛋白加酮酸饮食可改善5/6肾切除大鼠的血脂及肾功能,并可能通过抑制肾组织的慢性炎症反应,减轻残肾组织肾小球硬化和肾间质的病变程度,减少尿蛋白的排泄,从而延缓大鼠慢性肾衰的进展。  相似文献   

14.
目的:观察肾康灵在5/6肾大部切除大鼠模型中对残肾的保护作用并探讨其可能的机制。方法:将50只大鼠随机分为5组:假手术组、模型组、苯那普利治疗组(10nag·kg^-1·d^-1)、肾康灵高剂量组(15g·kg^-1·d^-1)和肾康灵低剂量组(5g·kg^-1·d^-1)。8周后观察大鼠24h尿蛋白、BUN、Scr、Alb及肾脏病理改变,并用免疫组化法观察转化生长因子pI(TGF—β1)、Col—Ⅳ、纤连蛋白(FN)、层黏连蛋白(LN)的表达。结果:肾康灵高低剂量治疗组和苯那普利治疗组尿蛋白排出量、肌酐、尿素氮水平明显低于模型组,血浆白蛋白水平高于模型组(P〈0.05)。病理上,接受肾大部切除术的大鼠均可见基质增生、肾小球硬化,但与模型组相比,用药组肾小球硬化程度明显减轻,其中肾康灵高剂量组肾小球硬化程度最轻;免疫组化结果显示用药组TGF-β1均明显低于模型组(P〈0.01),且肾康灵高、低刺量组与苯那普利组之间比较无统计学意义(P〉0.05)。结论:肾康灵对5/6肾大部切除大鼠肾脏有明显保护作用,其机制可能与其能减少肾组织中TGF-β1的表达、减少细胞外基质、降低蛋白尿等有关。  相似文献   

15.
《Renal failure》2013,35(8):726-735
Aldosterone is reported to promote fibrosis of multiple organs. Recent studies showed that Na+-H+ exchanger isoform 1 (NHE1) was involved in mineralocorticoid-induced tissue fibrosis. The present study examined the role of NHE1 in aldosterone-induced glomerulosclerosis in rats. SD male rats were subjected to 5/6 nephrectomy and divided into four groups: rats subjected to sham operation were used as control (SHAM group), 5/6 nephrectomy (SNX group), SNX treated with aldosterone via osmotic mini-pump (ALDO group), and SNX treated with aldosterone plus NHE1 inhibitor 5-(N, N-Dimethyl) amiloride hydrochloride (DMA) (ALDO+DMA group). The rats were sacrificed at the 12th week. We found that aldosterone treatment significantly increased kidney weight/body weight ratio and systolic blood pressure compared with SNX rats. Aldosterone also increased proteinuria and serum creatinine level. The NHE1 antagonist DMA significantly reversed the effect of aldosterone on proteinuria, but had no effect on the aldosterone associated hypertension and the elevation of serum creatinine. The remnant kidney of 5/6 nephrectomized rats exhibited increased glomerulosclerosis score, tubulointerstitial fibrosis, and tubular proteinaceous cast, which were significantly enhanced by aldosterone treatment. DMA treatment significantly reduced aldosterone-associated glomerulosclerosis, but failed to improve aldosterone-induced tubulointerstitial fibrosis and tubular proteinaceous cast. The aldosterone-induced increase in renal TGFβ1 and PCNA was significantly prevented by treatment with DMA. Our data showed that NHE1 inhibitor reduced aldosterone-induced glomerulosclerosis but not hypertension in 5/6 nephrectomized rats. The present study suggested that NHE1 contributed to aldosterone-induced-glomerulosclerosis and could be a potential therapeutic target for chronic kidney disease.  相似文献   

16.
目的 观察低蛋白配伍α酮酸饮食对肾大部切除大鼠残肾组织硬化和肾素血管紧张素系统(RAS)的影响。 方法 30只雄性SD大鼠建立肾大部切除的肾衰竭模型,1周后根据不同喂养分组如下:正常蛋白组(NPD组)予18%酪蛋白,低蛋白组(LPD组)予6%酪蛋白,低蛋白+α酮酸组(LK组)予5%酪蛋白+1%α酮酸,每组10只大鼠。另取10只雄性SD大鼠行假手术后予正常蛋白(18%酪蛋白)饲料作对照。12周后麻醉处死大鼠,常规检测生化指标和24 h尿蛋白定量。糖原染色法观察残肾组织的病理改变。免疫组化和Western印迹法检测残肾组织中转化生长因子(TGF-β1)、肾素(renin)和血管紧张素Ⅱ的1型受体(AT1R)的蛋白表达。实时PCR法检测renin和AT1R的基因表达。放免法和酶联免疫吸附法(ELISA)分别测定皮质匀浆和血浆中血管紧张素Ⅱ(AngⅡ)的含量。 结果 术后12周大鼠的体质量,血清总蛋白和白蛋白水平在各组间的差异无统计学意义(均P > 0.05)。肾衰竭模型大鼠的血肌酐和尿蛋白水平均较对照组显著升高(均P < 0.05),但3组间血肌酐水平的差异均无统计学意义(均P > 0.05),而LK组的尿蛋白水平较NPD组和LPD组显著降低(均P <0.05)。肾衰竭模型大鼠的肾小球硬化评分、ECM/肾小球面积之比和TGF-β1表达均显著高于对照组,而LK组和LPD组均显著低于NPD组(均P < 0.05)。肾皮质肾素、AngⅡ和AT1R的表达在LK组中均较NPD组显著降低(均P < 0.05)。 结论 在肾大部切除肾衰竭大鼠中,低蛋白配伍α酮酸饮食能在保证营养状态稳定的情况下减轻残肾组织的硬化,减少尿蛋白量,此肾脏保护作用可能与减轻肾脏局部RAS的活性有关。  相似文献   

17.
Several studies have shown that hepatocyte growth factor (HGF) ameliorates chronic renal failure, but its mechanism of action is unclear. This study was designed to test the delivery of HGF in the PCI-neo vector, using the 5/6 nephrectomized rat as a model for chronic renal failure, and to confirm that this protective function is associated with decreased protein expression of transforming growth factor-beta1 (TGF-β1). Rats were randomly divided into the following groups: Control (untreated), PCI-neo (vector control), 5/6 nephrectomy, and PCI-neo-HGF. Rats were sacrificed at both the fifth and ninth week after 5/6 nephrectomy. Kidney specimens were used for pathological examination (hematoxylin–eosin staining), and detection of TGF-β1 protein (Western blot and immunohistochemistry) expression. Blood urea nitrogen, serum creatinine, and 24-h urinary protein excretion (UPE) were increased, renal interstitium was seriously injured, and TGF-β1 protein expression was elevated in 5/6 nephrectomized rats compared to control rats at either time point. Red blood cell and hemoglobin levels decreased in the ninth week after 5/6 nephrectomy. PCI-neo-HGF expression ameliorated the aforementioned changes and decreased TGF-β1 expression, not only in the fifth week, but also in the ninth week after surgery. The process of renal injury in the 5/6 nephrectomized rat was consistent with that of chronic renal failure. The increase in TGF-β1 expression was maintained after 5/6 nephrectomy. HGF relieved chronic renal failure, this protection was associated with down-regulation of TGF-β1 protein expression, and the protective effects were long-term and stable after 5/6 nephrectomy.  相似文献   

18.
BACKGROUND: Nitric oxide (NO) plays an important role in the modulation of glomerular disease. The renal protective effect of resveratrol (RVT), a polyphenolic phytoalexin, was investigated in the 5/6th nephrectomized rats. MATERIALS AND METHODS: Resveratrol (5 mg/kg, PO) was administered for 12 weeks to 5/6th nephrectomized (NX) rats together with and without nitro L-arginine methyl ester (L-NAME) (10 mg/kg, IP). We evaluated the effect of these agents on proteinuria, hypertension, renal function, glomerulosclerosis, and urinary excretion of nitric oxide metabolites. RESULTS: 5/6th NX resulted in elevation in systolic blood pressure (SBP), reduced the urinary excretion of NO metabolites, increased urinary protein excretion, and deranged renal function and glomerulosclerosis. Treatment of animals with resveratrol significantly attenuated the increase in SBP, preserved the normal renal function, reduced the urinary protein excretion, increased the urinary excretion of NO metabolites, and prevented the glomerulosclerosis. Co-administration of animals with L-NAME along with resveratrol prevented the protection observed with resveratrol. CONCLUSION: These findings indicate that resveratrol exerts its protective effect in 5/6 NX rats through a nitric oxide pathway.  相似文献   

19.
N L Wong  E F Wong 《Nephron》1991,57(1):89-93
Indirect evidence suggests that atrial natriuretic peptide (ANP) secretion is augmented in chronic renal disease. The object of our present study is to examine the release of ANP from isolated atria obtained from chronic renal failure rats to directly determine whether ANP secretions are increased under these conditions. Experiments were conducted on male Wistar rats (200-225 g) who were subjected to 5/6 nephrectomy of sham operation. Plasma blood urea nitrogen was significantly elevated in 5/6 nephrectomized rats (65 +/- 7 vs. 16 +/- 1 mg%). Overall glomerular filtration rate was 2.36 +/- 0.06 ml/min in sham-operated animals, as opposed to 0.55 +/- 0.11 ml/min in 5/6 nephrectomized rats. Fractional excretion of sodium was significantly higher in 5/6 nephrectomized rats (0.52 +/- 0.01 vs. 1.68 +/- 0.21%). Plasma ANP was 102 +/- 4 pg/ml in normal rats and 161 +/- 14 pg/ml in 5/6 nephrectomized ones. We have also measured immunoreactive ANP in the atria of normal and 5/6 nephrectomized rats. ANP content and concentration in the atria were lower in 5/6 nephrectomized rats. (652 +/- 34 vs. 515 +/- 46 ng/mg of tissue). Right atria from normal and nephrectomized animals was superfused with a modified Langendorff preparation. Spontaneous release of ANP was significantly higher from the nephrectomized rats (17.5 +/- 0.6 pg/min/mg) than from the normal rats (9.8 +/- 0.3 pg/min/mg). These results suggest that ANP may play a role in sodium homeostasis in rats with reduced renal mass.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号